– Phase 3 Results from ARTISTRY-1 and 2 Trials will Form the Basis of Regulatory Submissions – Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 ...

WHO’s 2025 HIV clinical guidelines simplify and strengthen care by recommending more durable, safer treatment regimens, ...

Viral suppression is one of the major goals of the Centers for Disease Control and Prevention (CDC) Ending the HIV Epidemic in the US (EHE) initiative. 1 Viral suppression is defined in this context ...

GlaxoSmithKline subsidiary ViiV Healthcare achieved positive results in its Phase III clinical trials for a new two-drug regimen to treat HIV, reports The Wall Street Journal. Viiv Healthcare ...

A Q&A With Kassem Bourgi, MD. BOURGI: Each year, perhaps 10% to 15% of virologically suppressed patients on a stable regimen explore treatment switching. Most patient-initiated requests are motivated ...

Key goals of EHE include, from 2017 to the end of 2025, reducing new HIV infections and diagnoses by 75%, increasing viral suppression among PWH to 95%, and increasing good or better self-rated health ...

NEW YORK (Reuters Health) - A review of antiretroviral treatment (ART) regimens initiated in HIV-infected women revealed that nearly half of the regimens were either not specifically recommended for ...

Learn about the medical advancements and challenges faced by older adults living with HIV. Experts and survivors share their insights.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses of adults with HIV who are ...

Gilead Sciences, Inc. GILD announced that its investigational single-tablet regimen (STR) of bictegravir and lenacapavir for HIV-1 Treatment met the primary endpoint in the late-stage ARTISTRY-1 study ...